Medicare Enrolled
Dr. Charles Wykoff, MD, PHD
Retina Specialist (Ophthalmology) Physician · Bellaire, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Wykoff from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wykoff?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Wykoff
Dr. Charles Wykoff is a retina specialist physician in Bellaire, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Wykoff performed 32,697 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Wykoff received a total of $1,421,067 from 49 pharmaceutical and/or device companies across 746 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Wykoff is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 7% volume in TX
$1,421,067 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗32,697
Medicare services
Top 7% in TX for retina specialist (ophthalmology) physician
Not available
Unique patients (not deduplicated)
$191
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
12,671 | $29 | $113 |
| Aflibercept eye injection (Eylea) | 4,844 | $688 | $2,703 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
3,494 | $29 | $127 |
| Pegcetacoplan intravitreal injection, 1 mg An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram. |
3,135 | $120 | $451 |
| Injection, ranibizumab, 0.1 mg | 2,872 | $180 | $774 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
2,609 | $99 | $493 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
1,938 | $89 | $396 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
419 | $1,984 | $7,671 |
| Ranibizumab-eqrn injection, 0.1 mg An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose. |
207 | $219 | $840 |
| Comprehensive eye exam, new patient A comprehensive examination of the visual system performed for a new patient. |
117 | $101 | $469 |
| Unclassified biologic A biologic product that does not have a specific HCPCS code assigned. |
102 | $1,953 | $6,981 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
80 | $92 | $400 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
68 | $117 | $521 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
58 | $28 | $116 |
| Removal of eye fluid | 24 | $121 | $370 |
| Retinal photocoagulation to prevent detachment This procedure uses laser light to create small burns on the retina. It is performed to help prevent the retina from detaching from the back of the eye. |
20 | $186 | $752 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
16 | $102 | $394 |
| Fluorescein angiography of retina A special camera captures images of the blood vessels in the retina and the area between the white part of the eye and the retina after a dye is injected. |
12 | $206 | $788 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
11 | $64 | $280 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$1,421,067
Total received (2018-2024)
Avg $203,010/year across 7 years
Top 1% in TX for retina specialist (ophthalmology) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
746
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$394,856
2023
$193,077
2022
$113,172
2021
$142,174
2020
$207,700
2019
$205,010
2018
$165,077
Payments by company (2024)
EyePoint Pharmaceuticals US, Inc.
$115,944
Boehringer Ingelheim International GmbH
$96,887
Apellis Pharmaceuticals, Inc.
$72,629
ABBVIE INC.
$37,789
Regeneron Pharmaceuticals, Inc.
$17,848
SANOFI US SERVICES INC.
$13,113
Alcon Vision LLC
$7,250
F. Hoffmann-La Roche AG
$6,780
Boehringer Ingelheim Pharmaceuticals, Inc.
$4,750
Kowa Research Institute, Inc.
$4,500
BioCryst Pharmaceuticals, Inc.
$4,462
Bayer Healthcare Pharmaceuticals Inc.
$2,520
Bausch & Lomb Americas Inc.
$2,034
Janssen Pharmaceuticals, Inc
$1,815
Alimera Sciences, Inc.
$1,410
Janssen Research & Development, LLC
$1,200
Hexal AG
$1,075
Janssen Global Services, LLC
$1,000
Carl Zeiss Meditec, Inc.
$810
Genentech, Inc.
$785
Regeneron Healthcare Solutions, Inc.
$130
Genentech USA, Inc.
$80
Biogen, Inc.
$44
Top 3 companies account for 72.3% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Healthcare Solutions, Inc.
$182,258
Apellis Pharmaceuticals, Inc.
$152,713
EyePoint Pharmaceuticals US, Inc.
$142,506
Regeneron Pharmaceuticals, Inc.
$122,833
Boehringer Ingelheim International GmbH
$120,354
Novartis Pharma AG
$102,246
F. Hoffmann-La Roche AG
$85,807
Genentech, Inc.
$80,892
Novartis Pharmaceuticals Corporation
$76,602
Janssen Research & Development, LLC
$45,073
ABBVIE INC.
$40,056
Allergan Inc.
$31,406
SANOFI US SERVICES INC.
$26,646
Genentech USA, Inc.
$21,848
Janssen Global Services, LLC
$19,558
Alimera Sciences, Inc.
$18,670
Alcon Vision LLC
$14,225
Takeda Pharmaceuticals U.S.A., Inc.
$13,175
Allergan, Inc.
$12,648
AbbVie Inc.
$11,656
NOVARTIS PHARMACEUTICALS CORPORATION
$10,212
Shire North American Group Inc
$8,574
Merck Sharp & Dohme LLC
$8,176
Merck Sharp & Dohme Corporation
$8,175
Bausch & Lomb, a division of Bausch Health US, LLC
$7,977
Bausch & Lomb Americas Inc.
$7,552
Hexal AG
$7,525
Dutch Ophthalmic, USA
$5,000
Boehringer Ingelheim Pharmaceuticals, Inc.
$4,750
Kowa Research Institute, Inc.
$4,500
BioCryst Pharmaceuticals, Inc.
$4,462
Thrombogenics, Inc.
$3,750
Alnylam Pharmaceuticals Inc.
$3,640
Astellas Pharma US Inc
$3,600
Bayer Healthcare Pharmaceuticals Inc.
$2,520
Alcon Research LLC
$2,051
Janssen Pharmaceuticals, Inc
$1,815
Hoffmann-La Roche Limited
$1,570
NotalVision
$1,125
Aerie Pharmaceuticals, Inc.
$998
Carl Zeiss Meditec, Inc.
$880
Ocular Therapeutix, Inc.
$286
OPTOVUE, INC.
$236
Biogen, Inc.
$174
Coherus Biosciences Inc.
$133
Alcon Laboratories Inc
$96
Spark Therapeutics, Inc.
$82
Horizon Therapeutics plc
$19
Mallinckrodt Enterprises LLC
$16
Top 3 companies account for 33.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · BEOVU · BLZ_BEOVU_OPHTHALMOLOGY · BROLUCIZUMAB · BVU_BEOVU_OPHTHALMOLOGY · BYOOVIZ · CIRRUS HD-OCT · Cimerli · Constellation · DEXTENZA · DUREZOL · EVA Ophthalmic Surgical System · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYP-1901 · ForeseeHome · ILUVIEN · Iluvien · Izervay · Jetrea · LUXTURNA · Lucentis · Non-Covered Product · OZURDEX · RTH258A_BEOVU_OPHTHALMOLOGY · STELLARIS · SUSVIMO · SYFOVRE · Syfovre · TAKHZYRO · TEPEZZA · VABYSMO · VEOPOZ · VISUDYNE · VYZULTA · Vabysmo · XIPERE · XR · YUTIQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Retina specialist physicians in nearby ZIP areas
19
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
BEHAVIORAL HOSPITAL OF BELLAIRE
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Wykoff is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Wykoff experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Wykoff performed 12,671 eye injection (vabysmo/faricimab) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Wykoff receive payments from pharmaceutical companies?
Yes. Dr. Wykoff received a total of $1,421,067 from 49 companies across 746 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Wykoff's costs compare to other retina specialist physicians in Bellaire?
Dr. Wykoff's average Medicare payment per service is $191. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Wykoff) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Retina Specialist Physicians in Bellaire
Browse retina specialist physicians in Bellaire ranked by procedure volume and transparency data.
Highest volume
Top Retina Specialist Physicians in TX
Retina specialist physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Retina Specialist Physicians in TX
Which TX retina specialist physicians receive the most from drug and device companies.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
Apellis Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Apellis Pharmaceuticals, Inc.
By company
EyePoint Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from EyePoint Pharmaceuticals US, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology